Skip to main content
Clinical Trials/NCT05266092
NCT05266092
Recruiting
Not Applicable

Activation of the Contact System and the Immune System in Patients With Chronic Kidney

Odense University Hospital1 site in 1 country400 target enrollmentApril 25, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Kidney Disease Requiring Chronic Dialysis
Sponsor
Odense University Hospital
Enrollment
400
Locations
1
Primary Endpoint
Plasma level of cHK
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

Patients with end-stage renal disease undergoing hemodialysis (HD) are burdened with extremely high mortality rates (15% per year) and during the early stage (≤120days) the mortality rate is even higher (27% per year). Cardiovascular complications and bloodstream infections (BSIs) account for the vast majority of deaths in HD patients. In Denmark, BSIs occur in 14% of HD patients per year and is most frequently caused by Staphylococcus aureus (44%). The most frequent infectious complication is endocarditis that has fatal outcomes in ≈50% of the cases. Overall, 10% of HD patients die within 30 days after a positive blood culture for S. aureus. This project aims to answer key questions regarding HD patients' decreased ability to fight S. aureus BSIs and in particular the potential exacerbating effect of HD. We hypothesize that HD patients' blood is significantly compromised by the process of HD, to an extend that lowers immunoactivity against S. aureus. Moreover, we hypothesize, that contact activation promotes the coagulability of blood thus promoting biofilm formation by S. aureus which increases the overall risk of BSI. We will test these hypotheses by collecting blood and analyzing the inflammation and coagulation status in plasma samples from participants before and after HD. We will compare the level of the inflammatory markers in plasma from participants undergoing HD (n=180) to the level in plasma samples from three control groups: healthy volunteers (n=120), participants with renal disease not in dialysis (n=60) and participants undergoing peritoneal dialysis (n=40).

Registry
clinicaltrials.gov
Start Date
April 25, 2022
End Date
April 2032
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Katrine Pilely

Postdoc

Odense University Hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Plasma level of cHK

Time Frame: At enrollment

cHK is the final activation product of the contact activation system

Study Sites (1)

Loading locations...

Similar Trials